Business Summary
- research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.;
- production of pharmaceutical active ingredients (5.1%).
Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).
Number of employees: 1,505
Managers
Managers | Title | Age | Since |
---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 44 | - |
Director of Finance/CFO | 64 | 01/03/01 | |
Dmitry Saikovky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Eric Ivanovsky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrejs Liberts
PRN | Corporate Officer/Principal | 39 | 24/21/24 |
Iveta Zomerfelde
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kirovs Lipmans
CHM | Chairman | 83 | 01/03/01 |
Anna Lipmane
BRD | Director/Board Member | 76 | 01/08/01 |
Filips Lipmans
BRD | Director/Board Member | 46 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,585,000 | 308,478 ( 3.218 %) | 0 | 3.218 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+19.43% | 43.74B | |
+21.99% | 22.26B | |
+16.41% | 14.9B | |
+9.53% | 13.39B | |
+42.38% | 12.12B | |
-9.64% | 6.92B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.41% | 5.47B |